CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 39 enrolled
Drug / intervention
SM-1 +2 moredrug
Likely dose
SM-1 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02671760
NCT02671760Phase 2Completed

A Randomized, Double-Blind, Single-Dose Study to Assess the Pharmacodynamic Effects of SM-1 Versus Comparator and Placebo in a 5 Hour Phase Advance Model of Insomnia in Adults Who Suffer From Short-Term Insomnia

Sequential Medicine Ltd·interventional·Posted Feb 2, 2016·Updated Mar 6, 2018

In Brief

A Phase 2 clinical trial evaluating SM-1, Comparator, and 1 other intervention for Short-term Insomnia. Completed, enrolled 39 participants.

Detailed Summary

The purpose of this study is to evaluate the effect of a combination drug product containing diphenhydramine, zolpidem and lorazepam on total sleep time. Participants will be adults who sometimes have difficulty falling asleep or staying asleep, but who do not have chronic insomnia. The study involves 3 one-night stays in a sleep center in New York City.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
CollaboratorsClinilabs, Inc.

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2, 2016
Enrollment StartFeb 1, 2016
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 10.4 years ago

Interventions

SM-1drug

3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam

Comparatordrug

2-drug combination comprised of 5 mg zolpidem and 0.5 mg lorazepam

Placebodrug

Placebo